Breast Cancer
Conditions
Interventions
experimental group:Using High-throuphput Drug Sensitivity & Functional Genes Analysis Strategy to Guide the Clinical Application
Sponsors
Southwest Hospital, Army Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) The age is between 18-75 years old; (2) Relapsed and metastatic advanced breast cancer patients but the treatment (unlimited number of lines) is evaluated as stable or progressive disease; (3) Receiving neoadjuvant therapy but the clinical therapeutic effect is evaluated as stable or progressive disease; (4) Need to perform puncture or surgery; (5) The expected survival period is greater than 3 months; (6) ECOG physical status score is 0-1; (7) KPS score is greater than 60; (8) Bone marrow function: neutrophil >= 1.5 x 10^9 / L, platelet >= 100 x 10^9 / L, hemoglobin >= 90g / L; (9) Liver and kidney function: serum creatinine <= 1.5 times the upper limit of normal value; AST and ALT <= 2.5 times the upper limit of normal value; total bilirubin <= 1.5 times the upper limit of normal value, or <= 2.5 times the normal value when the patient has Gilbert's syndrome Upper limit; (10) Patients must have the ability to understand and voluntarily sign informed consent.
Exclusion criteria
Exclusion criteria: (1) New York Heart Association (NYHA) scores identify patients with heart disease above grade II (including grade II); (2) Patients with severe systemic infection or accompanied by other serious diseases; (3) Patients who are known to be allergic or intolerant to chemotherapy drugs or their accessories; (4) Other malignant tumors have occurred in the past 5 years, except for cured cervical carcinoma in situ and non-melanoma skin cancer; (5) During pregnancy or lactation, and patients of childbearing age who refused to take appropriate contraceptive measures during the trial; (6) Participated in other experimental studies within 30 days before the first dose of study drug; (7) The investigator judges that it is not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| High-throuphput Drug Sensitivity;Gene testing;Survival situation; | — |
Countries
China
Contacts
Public ContactXiaowei Qi
Southwest Hospital of Army Medical University
Outcome results
None listed